GlassScriptPhysician profile
Jessica Brutsky
NPI 1326764358
$3,024.89
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.01 · 2023: $2,054 · 2024: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $378.49 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.99 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $283.69 | 2023-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $264.99 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $251.96 | 2022-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $244.74 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.52 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $198.07 | 2023-2024 | |
| Amgen INC. | $172.65 | 2022-2024 | Repatha |
| Abbott Laboratories | $150.92 | 2023 | Jot Dx, Merlin@Home |
| Actelion Pharmaceuticals US, INC. | $149.99 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $108.40 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $91.04 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $40.94 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $33.82 | 2023 | Evkeeza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $26.76 | 2023 | Arcalyst |
| Medicomp INC | $22.56 | 2023 | Telepatch Cardiac Monitor |
| Fresenius Kabi USA, LLC | $22.26 | 2023 | Stimufend |
| Scpharmaceuticals INC. | $21.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Brutsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.